Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 20/20 | 1.00 |
| ▸ | WDR77 | Q9BQA1 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21355984 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL27262945 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL29470697 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL29470779 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL29380833 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24910109 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL29383740 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| Hydrochloric Acid SCHEMBL30713702 | 0.99 | PRMT5 (0.98) | PRMT5WDR77 | |
| Hydrochloric Acid SCHEMBL30713703 | 0.99 | PRMT5 (0.98) | PRMT5WDR77 | |
| SCHEMBL21355969 | 0.95 | PRMT5 (1.00) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765461-B1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2023-08-30 | — | — | EP | claimed |
| US-11254683-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-02-22 | — | — | US | claimed |
| US-20200361945-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2020-11-19 | — | — | US | claimed |
| US-10711007-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2020-07-14 | — | — | US | claimed |
| US-20190284193-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2019-09-19 | — | — | US | claimed |
| US-20250367205-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250361258-A1 | PROCESSES FOR MAKING PRMT5 INHIBITORS | PRELUDE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12459950-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2025-11-04 | — | — | US | disclosed |
| US-12440506-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| US-12414953-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250197418-A1 | Polymorphic Compounds And Uses Thereof | PRELUDE THERAPEUTICS INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250163074-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2025-05-22 | — | — | US | disclosed |
| WO-2020206299-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20200291037-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291037-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-10711007-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2020-07-14 | — | — | US | disclosed |
| US-10711007-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190284193-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2019-09-19 | — | — | US | disclosed |
| US-20190284193-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2019-09-19 | — | — | US | disclosed |
| WO-2019178368-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163074-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | PRMT5 571/4885WDR77 1435/4885 |
| US-12459950-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885 |
| US-10711007-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885 |
| US-11254683-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885 |
| US-20200361945-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885 |
| US-12440506-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 57/4885 |
| US-20250197418-A1 | Polymorphic Compounds And Uses Thereof | CDK6, CDK4, CDK8 | PRMT5 2109/4885WDR77 732/4885 |
| US-20250361258-A1 | PROCESSES FOR MAKING PRMT5 INHIBITORS | PRMT1, PRMT5, PRMT6 | PRMT5 2/4885WDR77 83/4885 |
| US-20250367205-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 100/4885 |
| US-20190284193-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885 |
| US-12414953-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 100/4885 |
| US-20200291037-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.